Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/TCRM.S84151 http://scihub22266oqcxt.onion/10.2147/TCRM.S84151 C4603718!4603718!26504398     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Clin+Risk+Manag 2015 ; 11 (ä): 1563-72 Nephropedia Template TP {{tp|p=26504398|t=2015. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD |pdf=|usr=}}{{26504398}} gab.com Text Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD JO: Ther Clin Risk Manag http://www.kidney.de/pget.php?&tw=1&pmid=26504398 #FOAvip Bronchodilators are the most important drugs used for the treatment of chronic obstructive pulmonary disease (COPD). In particular, these therapeutic agents are mostly long-acting compounds utilized via inhalation, and include LAMA (long-acting muscarinic receptor antagonists) and LABA (long-acting ?2-adrenoceptor agonists). Because LAMA and LABA induce bronchodilation by distinct mechanisms of action, LABA/LAMA combinations provide a reciprocal potentiation of the pharmacological effects caused by each component. Hence, many COPD patients who do not achieve a satisfactory control of their symptoms using a single, either LAMA or LABA bronchodilator, can experience relevant benefits with the use of LAMA/LABA fixed combinations. Many different LAMA/LABA combinations have been recently developed and evaluated in randomized clinical trials. In this context, our review focuses on the pharmacological mechanisms underpinning the bronchodilation elicited by the LAMA tiotropium bromide and the LABA olodaterol. We also discuss the results of the most important clinical studies carried out in COPD patients to assess the efficacy and safety of tiotropium/olodaterol combinations. Twit Text FOAVip Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD ????Ther Clin Risk Manag http://www.kidney.de/pget.php?&tw=1&pmid=26504398 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26504398 #FOAvip English Wikipedia <ref>{{Cite pmid|26504398}}</ref> Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD #MMPMID26504398 Pelaia G; Vatrella A; Busceti MT; Gallelli L; Calabrese C; Terracciano R; Lombardo N; Maselli R Ther Clin Risk Manag 2015[]; 11 (ä): 1563-72 PMID26504398show ga Bronchodilators are the most important drugs used for the treatment of chronic obstructive pulmonary disease (COPD). In particular, these therapeutic agents are mostly long-acting compounds utilized via inhalation, and include LAMA (long-acting muscarinic receptor antagonists) and LABA (long-acting ?2-adrenoceptor agonists). Because LAMA and LABA induce bronchodilation by distinct mechanisms of action, LABA/LAMA combinations provide a reciprocal potentiation of the pharmacological effects caused by each component. Hence, many COPD patients who do not achieve a satisfactory control of their symptoms using a single, either LAMA or LABA bronchodilator, can experience relevant benefits with the use of LAMA/LABA fixed combinations. Many different LAMA/LABA combinations have been recently developed and evaluated in randomized clinical trials. In this context, our review focuses on the pharmacological mechanisms underpinning the bronchodilation elicited by the LAMA tiotropium bromide and the LABA olodaterol. We also discuss the results of the most important clinical studies carried out in COPD patients to assess the efficacy and safety of tiotropium/olodaterol combinations. äPharmacologic rationale underlying the therapeutic effects of tiotropi(epmc).pdf DeepDyve Pubget Overpricing